Robin Siperstein, MD, FAAD, shares practical tips in cosmetic dermatology at the 2024 SDPA Annual Summer Dermatology Meeting.
Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.
Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.
Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.
Caleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.
Jamie Restivo, MPAS, PA-C, shares some insights from the 5th Annual Keystone Dermatology Conference held from October 17 to 19 in Philadelphia, Pennsylvania.
The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.
Experts in dermatology share closing thoughts on the management of plaque psoriasis.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.
As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.
Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, provide initial impressions of the case and discuss the use of immune checkpoint inhibitors.
The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.
To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.
Congenital malalignment syndrome is a nail disorder caused by the lateral rotation of the nail matrix.
Following this week's Science of Skin media roundtable hosted by AbbVie, panelist and dual-board certified dermatologist and psychiatrist Evan Rieder, MD, discusses the relationship between chronic skin conditions and mental health.
Omer Ibrahim, MD, discusses the nuances of aesthetic procedures for patients with skin of color and the importance of tailored treatments, safety, and improved clinician education.
Though providers probably can use any type of medical software, the financial resources they are able to invest in medical solutions differ significantly based on the type of practice.
Panelists discuss how factors such as tumor size, location, patient age, and overall health guide the decision between surgical excision and nonsurgical treatments such as topical therapies or radiation for managing basal cell carcinoma (BCC) effectively.
Megan Noe, MD, MPH, MSCE, reviews best practices for treating patients with cutaneous blisters and managing chronic bullous disorders.
Allergist immunologist Giselle Mosnaim, MD, recently spoke with Dermatology Times to discuss late-breaking phase 3 REMIX-1 and REMIX-2 data presented at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.
Research showed that many patients with skin cancer who had been treated using immunotherapy, such as immune checkpoint inhibition, experienced chronic side effects.
His keynote speech at ACMS focused on artificial intelligence for precision medicine and cancer diagnosis.